Acasti Pharma, Inc. - (ACST): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACST Stock Price Chart Interactive Chart >
ACST Price/Volume Stats
| Current price | $0.42 | 52-week high | $1.79 |
| Prev. close | $0.41 | 52-week low | $0.37 |
| Day low | $0.40 | Volume | 39,000 |
| Day high | $0.42 | Avg. volume | 166,032 |
| 50-day MA | $0.56 | Dividend yield | N/A |
| 200-day MA | $0.88 | Market Cap | 18.69M |
Acasti Pharma, Inc. - (ACST) Company Bio
Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.
Latest ACST News From Around the Web
Below are the latest news stories about ACASTI PHARMA INC that investors may wish to consider to help them evaluate ACST as an investment opportunity.
Acasti Pharma Reports Second Quarter 2023 Operational ResultsCompany to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the second quarter ended September 30, 2022. Recent Highlights The Company expects to receive guidance from the Food and Drug Administration (FD |
Acasti Pharma to Present at Q4 Investor SummitLAVAL, Québec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that Jan D’Alvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit. The Company will be conducting a webcasted presentation and participating in one-on-one meetings with investors. Event: Q4 |
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022Call to be held on Monday, November 14th at 1:00 PM Eastern TimeLAVAL, Quebec, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call at 1:00 PM Eastern Time on Monday, November 14, 2022, to discuss the Company’s corporate progress and other developments, as well as |
Acasti Announces Court Dismissal of Stockholder LitigationLAVAL, Québec, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today that a U.S. court has dismissed the remaining stockholder litigation filed in connection with the Company’s acquisition of Grace Therapeutics, Inc. (“Grace”) via merger in August 2021 (the “Merger”). As previously disclosed, four st |
Acasti Announces Voting Results from 2022 Annual and Special Meeting of ShareholdersLAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) which was held virtually on Wednesday September 28, 2022. Election of Directors All five (5) nominees listed in the proxy statement dated |
ACST Price Returns
| 1-mo | -26.34% |
| 3-mo | -53.33% |
| 6-mo | N/A |
| 1-year | -69.57% |
| 3-year | -97.38% |
| 5-year | -96.93% |
| YTD | -66.67% |
| 2021 | -51.54% |
| 2020 | -86.73% |
| 2019 | 195.18% |
| 2018 | -11.70% |
| 2017 | -24.80% |
Loading social stream, please wait...